Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 7, 2015, Pages 1315-1320

  Al Homsi, Ahmad Samer ^a,b   Cole, Kelli ^a   Bogema, Marlee ^a   Duffner, Ulrich ^a,b   Williams, Stephanie ^a,b   Mageed, Aly ^a,b  

^a SPECTRUM HEALTH   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Allogeneic blood and marrow transplantation; Bortezomib; Graft versus host disease prophylaxis; Post transplantation cyclophosphamide

Indexed keywords

ACICLOVIR; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MYCOPHENOLATE MOFETIL; PREDNISONE; STEROID; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG SAFETY; EPSTEIN BARR VIRUS; FAINTNESS; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LIVER FUNCTION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; ORTHOSTATIC HYPOTENSION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RIGOR; SIDE EFFECT; T LYMPHOCYTE; UNRELATED DONORS; VENOUS THROMBOEMBOLISM; VIRUS REACTIVATION; ACUTE DISEASE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; MORTALITY; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROCEDURES; REGULATORY T LYMPHOCYTE; RISK; SIBLING; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; ANTILYMPHOCYTE SERUM; BORTEZOMIB; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK; SIBLINGS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84930573681     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.02.008     Document Type: Article

References (34)

1. Appelbaum F.R. Hematopoietic cell transplantation at 50. NEngl J Med 2007, 357:1472-1475.
2. Welniak L.A., Blazar B.R., Murohy W.J. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007, 25:139-170.
3. Remberger M., Ackefors M., Berglund S., et al. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant 2011, 17:1688-1697.
4. Arai S., Arora M., Wang T., et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation-a report from CIBMTR. Biol Blood Marrow Transplant 2015, 21:266-274.
5. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. NEngl J Med 1986, 314:729-735.
6. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
7. Luznik L., O'Donnell P.V., Fuchs E.J. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical BMT. Semin Oncol 2012, 39:683-693.
8. Al-Homsi A.S., Roy T.S., Cole K., et al. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant 2015, 21:604-611.
9. Ross D., Jones M., Komanduri K., Levy R.B. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013, 19:1430-1438.
10. Berges C., Haberstock H., Fuchs D., et al. Proteasome inhibition suppresses immune functions of human CD4+ T cells. Immunology 2008, 124:234-246.
11. Nencioni A., Garuti A., Schwarzenberg K., et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 2006, 36:681-689.
12. Nencioni A., Grünebach F., Patrone F., et al. The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol 2006, 26:487-497.
13. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decrease the production of Th1 cytokines. Blood 2006, 107:3575-3583.
14. Liu W., Ren H.Y., Dong Y.J., et al. Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis. Int J Hematol 2012, 96:764-772.
15. Arpinati M., Chirumbolo G., Nicolini B., et al. Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade). Bone Marrow Transplant 2009, 43:253-259.
16. Nencioni A., Schwarzenberg K., Brauer K.M., et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006, 108:551-558.
17. Blanco B., Pérez-Simón J.A., Sánchez-Abarca L.I., et al. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T cell population. Haematologica 2009, 94:975-983.
18. Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 2004, 101:8120-8125.
19. Tao Y., Zhang W., Fang Y., et al. Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells. Exp Hematol 2011, 39:710-720.
20. Li Z., Wu Q., Yan Z., et al. The protection and therapy effects of bortezomib in murine acute graft-versus-host disease. Transplant Proc 2013, 45:2527-2535.
21. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. JClin Oncol 2012, 30:3202-3208.
22. Roccaro A.M., Vacca A., Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 2006, 1:397-403.
23. Lundqvist A., Abrams S.I., Schrump D.S., et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006, 66:7317-7325.
24. Storb R., Antin J.H., Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host-disease?. Biol Blood Marrow Transplant 2010, 16:S18-S27.
25. Cutler C., Logan B., Nakamura R., et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014, 124:1372-1377.
26. Luznik L., Bolaños-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
27. Kankary G.K., O'Donnell P.V., Furlong T., et al. Multi-institutional study of post-transplant cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. JClin Oncol 2014, 32:3497-3505.
28. Solomon S.R., Sanacore M., Zhang X., et al. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with post-transplant cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:1828-1834.
29. Mohty M., Brissot E., Savani B.N., Gaugler B. Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant 2013, 19:1416-1420.
30. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
31. Sun K., Wilkins D.E., Anver M.R., et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005, 106:3290-3299.
32. Liang Y., Ma S., Zhang Y., et al. IL-1β and TLR4 signaling are involved in the aggravate murine acute graft-versus-host disease caused by delayed bortezomib administration. JImmunol 2014, 192:1277-1285.
33. Al-Homsi A.S., Lai Z., Roy T., et al. Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IκB and NF-κB. Transpl Immunol 2013, 30:40-45.
34. Shadman M., Sandmaier B.M., Maloney D.G., et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with end stage renal disease requiring dialysis- a single institution experience. Biol Blood Marrow Transplant 2014, 20:S251.